Colitis, UlcerativePhase 2NCT01240915
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis
A Phase 2 study testing MultiStem low dose and MultiStem high dose in people with Colitis, Ulcerative, run by Pfizer at 58 sites in 8 countries.
Trial summary
MultiStem(r) is a new biological product, manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. Factors expressed by MultiStem cells are believed to reduce inflammation and regulate immune system function, protect damaged or injured cells and tissue, promote formation… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colitis, Ulcerative
- What is being tested?
- MultiStem low dose and MultiStem high dose
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 105 participants
- Where
- 58 sitesin 8 countries
- Study dates
- Feb 2011to Nov 2014
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects must have a documented diagnosis of ulcerative colitis at least 6 months prior to screening.
- Subjects must have active moderate-to-severe ulcerative colitis based on Mayo score.
- Subjects must have Modified Baron endoscopic score of at least 2 determined within 7 days of first dosing.
- Subjects must have failed or be intolerant (as determined by the investigator) of at least one of the following treatments for UC: Oral corticosteroids, azathioprine or 6-mercaptopurine (6-MP), or anti-tumor necrosis factor (TNF) therapy, eg, infliximab or adalimumab.
- Subjects must be on stable steroid doses.
Who cannot join
- Subjects who have abnormal organ and marrow function.
- Subjects with a diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn's disease.
- Subjects who meet Truelove-Witts criteria for severe ulcerative colitis.
- Subjects receiving or who are expected to receive Infliximab or other biologic treatment within 8 weeks of the Day 1 study visit.
- Subjects receiving or who are expected to receive Cyclosporine, mycophenolate, or tacrolimus within 4 weeks of the Day 1 study visit.
Trial locations and contacts
58 sites in 8 countries.
58 sites in 8 countries
United States37 sites
Charlotte Gastroenterology and Hepatology, PLLC
Charlotte, North Carolina, 28207
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan, 48047
Metropolitan Gastroenterology Group, PC - Chevy Chase Clinical Research
Chevy Chase, Maryland, 20815
University of Chicago Medical Center
Chicago, Illinois, 60637
Gastroenterology Consultants of Clearwater
Clearwater, Florida, 33756
West Coast Endoscopy Center
Clearwater, Florida, 33756
Clinical Research of West Florida, Inc.
Clearwater, Florida, 33765
Surgery Center of Columbia
Columbia, Missouri, 65201
Gastro One
Germantown, Tennessee, 38138
Borland-Groover Clinic
Jacksonville, Florida, 32256
Jacksonville Center for Endoscopy
Jacksonville, Florida, 32256
Clinical Research of the Rockies
Lafayette, Colorado, 80026
Rocky Mountain Gastroenterology Associates, LLC
Lakewood, Colorado, 80215
Arapahoe Gastroenterology, PC
Littleton, Colorado, 80120
University of Louisville Healthcare Outpatient Center
Louisville, Kentucky, 40202
University of Louisville Hospital
Louisville, Kentucky, 40202
Center for Digestive and Liver Diseases, Inc.
Mexico, Missouri, 65265
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-1375
Present, Chapman, Steinlauf and Marion
New York, New York, 10028
Mount Sinai School of Medicine
New York, New York, 10029
Asher Kornbluth, MD PC
New York, New York, 10128
Digestive and Liver Disease Specialists
Norfolk, Virginia, 23502
Sentara Leigh Hospital
Norfolk, Virginia, 23502
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
Wake Internal Medicine Consultants, Inc.
Raleigh, North Carolina, 27612
Wake Research Associates
Raleigh, North Carolina, 27612
McGuire DVAMC
Richmond, Virginia, 23249
University of California San Francisco
San Francisco, California, 94115
USCF Endoscopy Unit at Mount Zion
San Francisco, California, 94115
University of Washington Medical Center
Seattle, Washington, 98195
Miami Research Associates
South Miami, Florida, 33143
Cotton-O'Neil Clinical Research Center, Digestive Health
Topeka, Kansas, 66606
Endoscopic Microsurgery Associates, PA
Towson, Maryland, 21204
Center for Digestive Health
Troy, Michigan, 48098
Utica Surgery Center
Utica, Michigan, 48317
Metropolitan Gastroenterology Group, PC
Washington D.C., District of Columbia, 20006
Wake Forest University University Baptist Medical Center - Internal Medicine
Winston-Salem, North Carolina, 27157
Canada4 sites
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7
Northern Alberta Clinical Trials and Research Center
Edmonton, Alberta, T6G 2C8
Zeidler Ledcor Centre - University of Alberta
Edmonton, Alberta, T6G 2X8
Maisonneuve-Rosemont Hospital
Montreal, Quebec, H1T 2M4
Hungary4 sites
Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia
Budapest, 1125
Pandy Kalman Megyei Korhaz, III. sz. Belosztaly-Gasztroenterologia
Gyula, 5700
Karolina Korhaz Rendelointezet, Belgyogyaszat
Mosonmagyaróvár, 9200
Tolna Megyei Balassa Janos Korhaz / II. Belgyogyaszat
Szekszárd, 7100
Germany3 sites
Agaplesion Markus Krankenhaus
Frankfurt am Main, 60431
Universitaetsklinikum Halle
Halle, 06120
Medizinische Hochschule Hannover
Hanover, 30625
Italy3 sites
Azienda Ospedaliera Luigi Sacco
Milan, 20157
Azienda Ospedaliera di Padova
Padova, 35128
Policlinico Universitario Agostino Gemelli
Roma, 00168
Sweden3 sites
Sahlgrenska Universitetssjukhuset Medicinkliniken
Gothenburg, 413 45
Karolinska Universitetssjukhuset, GastroCentrum Medicin
Stockholm, 171 76
Akademiska sjukhuset, Mag tarmmottagningen
Uppsala, 751 85
Belgium2 sites
Hopital Erasme / Gastroenterology
Brussels, 1070
Pfizer Clinical Research Unit
Brussels, 1070
Slovakia2 sites
Gastroenterologicke a hepatologicke oddelenie, V. interna klinika LFUK a UN Bratislava, Ruzinov
Bratislava, Slovakia, 826 06
Gastroenterologicka ambulancia, GEA s.r.o.
Trnava, 917 01
About this study
Official title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Investigate The Safety And Efficacy Of Multistem (Pf-05285401) In Subjects With Moderate To Severe Ulcerative Colitis
MultiStem(r) is a new biological product, manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. Factors expressed by MultiStem cells are believed to reduce inflammation and regulate immune system function, protect damaged or injured cells and tissue, promote formation of new blood vessels, and augment tissue repair and healing. MultiStem cell treatment resulted in significant efficacy in a mouse model of Graft versus Host Disease with almost complete reversal of gastrointestinal pathology (similar to pathology that would be expected in Ulcerative Colitis). These data, together with safety data generated in 2 other clinical trials, suggest that MultiStem has the potential to be a new treatment option for patients with ulcerative colitis. This is the first study of MultiStem in this patient population and will cautiously explore the safety/toleration and potential benefit of this new treatment in patients with moderate to severe disease.
- Conditions
- Colitis, Ulcerative
- Being tested
- placebo, MultiStem low dose, MultiStem high dose
- Keywords
- safety efficacy MultiStem(r) moderate to severe Ulcerative Colitis
- Medical subject headings
- Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placeboDrug
once every 7 days for 1- 3 doses
MultiStem low doseDrug
1-3 doses
placeboDrug
Single dose at week 8
MultiStem low doseDrug
Single dose at week 8
placeboDrug
Single dose Day 1
MultiStem high doseDrug
Single dose Day 1
placeboDrug
Single dose at week 8
MultiStem high doseDrug
Single dose at week 8
placeboDrug
Single dose Day 1
MultiStem high doseDrug
Single dose Day 1
placeboDrug
Single dose at week 8
MultiStem high doseDrug
Single dose at week 8
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 | Experimental | The first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 \& 2). Receives: Drug: placebo; Drug: MultiStem low dose |
| Cohort 2 | Experimental | This group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8. Receives: Drug: placebo; Drug: MultiStem high dose |
| Cohort 3 | Experimental | These subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of ~22 patients will receive an additional infusion of MultiStem, ~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and ~22 patients will receive an additional infusion of placebo. Receives: Drug: placebo; Drug: MultiStem high dose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8
Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding).
Measured: Baseline and Week 8
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 4
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
Measured: Baseline and Week 4
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 8
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
Measured: Baseline and Week 8
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.
Measured: Baseline up to Week 52
Number of Participants With Treatment-Emergent AEs by System Organ Class (SOC)
Measured: Baseline up to Week 52
Number of Treatment-Emergent AEs by Severity
The intensity grades were defined as follows: mild=does not interfere with participant's usual function; moderate=interferes to some extent with participant's usual function; severe=interferes significantly with participant's usual function.
Measured: Baseline up to Week 52
Secondary outcomes (15)
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 12 and Week 16
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
Measured: Baseline, Week 12, Week 16
Number of Participants With Laboratory Test Abnormalities
The total number of participants with laboratory test abnormalities with or without regard to baseline abnormality was assessed. Laboratory parameters included: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, erythrocyte sedimentation rate); chemistry (blood urea nitrogen and creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein; urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, microscopy (only if urine dipstick was positive for blood, protein, nitrites or leukocyte esterase); other (follicle-stimulating hormone, human chorionic gonadotropin, stool microbiology, creatinine kinase, direct bilirubin, indirect bilirubin, gamma-glutamyl transferase, international normalized ratio.
Measured: Baseline up to Week 24
Number of Participants With Potentially Clinically Significant Vital Signs Findings
Vital signs assessment included pulse rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Criteria for vital sign values meeting potential clinical concern included: SBP <90 millimeters of mercury (mm Hg) and >=30 mm Hg increase/decrease from baseline, DBP <50 mm Hg and >=20 mm Hg increase/decrease from baseline, pulse rate <40 or >120 beats per minute (bpm),
Measured: Baseline up to Week 52
Fold Change From Baseline in Fecal Calprotectin at Weeks 4, 8, 12, and 16
Fecal calprotectin, a very stable marker, is a 36kDa calcium and zinc binding protein which is neutrophil-derived. It represents 60% of cytosolic proteins in granulocytes and is a measurement of neutrophil migration to the gastrointestinal tract.
Measured: Baseline, Weeks 4, 8, 12 and 16
Fold Change From Baseline in C-Reactive Protein (CRP) at Weeks 4, 8, 12, and 16
CRP is an acute-phase protein which provides an objective criterion of inflammatory activity. CRP has a short half-life (19 hours) and therefore rises early after the onset of inflammation and rapidly decreases after resolution of the inflammation. It is induced by interleukin-6, TNF-alpha and other pro-inflammatory cytokines that are produced within the intestinal lamina propria.
Measured: Baseline, Weeks 4, 8, 12 and 16
Percentage of Participants With Rectal Bleeding Mayo Subscore of Zero at Weeks 4, 8, 12, and 16
Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes).
Measured: Week 4, 8, 12 and 16
Percentage of Participants in Endoscopic Remission at Week 8
Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding). Endoscopic remission is defined as modified Baron Endoscopic Score equal to 0.
Measured: Week 8
Percentage of Participants in Clinical Remission at Week 8
Clinical remission is defined as a total Mayo score of 2 points or lower, with no individual subscores exceeding 1 point.
Measured: Week 8
Percentage of Participants With Decrease From Baseline of at Least 1 Point in Rectal Bleeding Mayo Subscore at Weeks 4, 8, 12, and 16
Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes). A decrease from baseline score indicates improvement.
Measured: Baseline, Weeks 4, 8, 12 and 16
Percentage of Participants With Endoscopic Response at Week 8
Endoscopic response is defined as a decrease in modified Baron endoscopic score from baseline of at least 2 points.
Measured: Week 8
Percentage of Participants in Clinical Response at Week 8
Clinical response is defined as a decrease in total Mayo score from baseline of at least 3 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore for rectal bleeding of 0 or 1.
Measured: Week 8
Change From Baseline in Total Mayo Scores at Week 8
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis, with total score ranging from 0 to 12. It consists of 4 subscores (stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy, and physician global assessment [PGA]), each graded from 0 to 3, with higher scores indicating more severe disease.
Measured: Baseline, Week 8
Change From Baseline in Partial Mayo Scores at Weeks 4, 8, 12, and 16
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo Score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. A Partial Mayo Score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each ranging from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Higher scores indicate more severe disease.
Measured: Baseline, Weeks 4, 8, 12 and 16
Change From Baseline in Biopsy Histology Scores at Week 8
A 15 to 25 centimeter (cm) biopsy sample of inflamed mucosal tissue was taken from the worst affected area and scored using the Riley Index. The Riley Index is a histologic scoring system for the assessment of the activity and severity of ulcerative colitis, ranging from 0 to 24. It consists of 6 histologic features (acute inflammatory cell infiltrate, crypt abscesses, mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate, and crypt architectural irregularities), all scored on a 4-point scale (higher scores indicate more severe disease).
Measured: Baseline and Week 8
Change From Baseline in Patient-Reported Rectal Bleeding up to Week 16
Patient-reported diary data assessed the number of bowel movements (BM) per day when not having a flare and the presence of blood in the stools (rectal bleeding [RB]), if any.
Measured: Baseline and Week 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Nov 2010 (estimated)
- Study startFeb 2011
- Primary completionNov 2014
- Study completionNov 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Colitis, UlcerativeStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 105 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Healios K.K.
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01240915
- Sponsor's protocol ID
- B3041001
- Other IDs
- 2010-022766-27
- Status last verified
- Jan 2016
- First submitted
- 10 Nov 2010
- Last updated
- 23 Feb 2016
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Investigate The Safety And Efficacy Of Multistem (Pf-05285401) In Subjects With Moderate To Severe Ulcerative Colitis
- ClinicalTrials.gov ID
- NCT01240915
- Acronym / sponsor ID
- B3041001
- Conditions
- Colitis, Ulcerative
- Keywords
- safety efficacy MultiStem(r) moderate to severe Ulcerative Colitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 105 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Collaborators
- Healios K.K.
- Study start
- Feb 2011
- Primary completion
- Nov 2014 (actual)
- Study completion
- Nov 2014 (actual)
- First posted
- 15 Nov 2010 (estimated)
- Results
- Posted 23 Feb 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
MultiStem(r) is a new biological product, manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. Factors expressed by MultiStem cells are believed to reduce inflammation and regulate immune system function, protect damaged or injured cells and tissue, promote formation of new blood vessels, and augment tissue repair and healing. MultiStem cell treatment resulted in significant efficacy in a mouse model of Graft versus Host Disease with almost complete reversal of gastrointestinal pathology (similar to pathology that would be expected in Ulcerative Colitis). These data, together with safety data generated in 2 other clinical trials, suggest that MultiStem has the potential to be a new treatment option for patients with ulcerative colitis. This is the first study of MultiStem in this patient population and will cautiously explore the safety/toleration and potential benefit of this new treatment in patients with moderate to severe disease.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 | Experimental | Drug: placebo, Drug: MultiStem low doseThe first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 \& 2). |
| Cohort 2 | Experimental | Drug: placebo, Drug: MultiStem high doseThis group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8. |
| Cohort 3 | Experimental | Drug: placebo, Drug: MultiStem high doseThese subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of ~22 patients will receive an additional infusion of MultiStem, ~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and ~22 patients will receive an additional infusion of placebo. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Subjects must have a documented diagnosis of ulcerative colitis at least 6 months prior to screening.
- Subjects must have active moderate-to-severe ulcerative colitis based on Mayo score.
- Subjects must have Modified Baron endoscopic score of at least 2 determined within 7 days of first dosing.
- Subjects must have failed or be intolerant (as determined by the investigator) of at least one of the following treatments for UC: Oral corticosteroids, azathioprine or 6-mercaptopurine (6-MP), or anti-tumor necrosis factor (TNF) therapy, eg, infliximab or adalimumab.
- Subjects must be on stable steroid doses.
Key exclusion criteria (5 listed)
- Subjects who have abnormal organ and marrow function.
- Subjects with a diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn's disease.
- Subjects who meet Truelove-Witts criteria for severe ulcerative colitis.
- Subjects receiving or who are expected to receive Infliximab or other biologic treatment within 8 weeks of the Day 1 study visit.
- Subjects receiving or who are expected to receive Cyclosporine, mycophenolate, or tacrolimus within 4 weeks of the Day 1 study visit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placeboonce every 7 days for 1- 3 doses | Drug | Cohort 1 |
| MultiStem low dose1-3 doses | Drug | Cohort 1 |
| placeboSingle dose at week 8 | Drug | Cohort 1 |
| MultiStem low doseSingle dose at week 8 | Drug | Cohort 1 |
| placeboSingle dose Day 1 | Drug | Cohort 2 |
| MultiStem high doseSingle dose Day 1 | Drug | Cohort 2 |
| placeboSingle dose at week 8 | Drug | Cohort 2 |
| MultiStem high doseSingle dose at week 8 | Drug | Cohort 2 |
| placeboSingle dose Day 1 | Drug | Cohort 3 |
| MultiStem high doseSingle dose Day 1 | Drug | Cohort 3 |
| placeboSingle dose at week 8 | Drug | Cohort 3 |
| MultiStem high doseSingle dose at week 8 | Drug | Cohort 3 |
Primary outcome
Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8
Time frame: Baseline and Week 8
Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding).
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 4
Time frame: Baseline and Week 4
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 8
Time frame: Baseline and Week 8
Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to Week 52
An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.
Number of Participants With Treatment-Emergent AEs by System Organ Class (SOC)
Time frame: Baseline up to Week 52
Number of Treatment-Emergent AEs by Severity
Time frame: Baseline up to Week 52
The intensity grades were defined as follows: mild=does not interfere with participant's usual function; moderate=interferes to some extent with participant's usual function; severe=interferes significantly with participant's usual function.
15 secondary outcomes
Change From Baseline in Rectal Bleeding Mayo Subscore at Week 12 and Week 16
Time frame: Baseline, Week 12, Week 16
Number of Participants With Laboratory Test Abnormalities
Time frame: Baseline up to Week 24
Number of Participants With Potentially Clinically Significant Vital Signs Findings
Time frame: Baseline up to Week 52
Fold Change From Baseline in Fecal Calprotectin at Weeks 4, 8, 12, and 16
Time frame: Baseline, Weeks 4, 8, 12 and 16
Fold Change From Baseline in C-Reactive Protein (CRP) at Weeks 4, 8, 12, and 16
Time frame: Baseline, Weeks 4, 8, 12 and 16
Percentage of Participants With Rectal Bleeding Mayo Subscore of Zero at Weeks 4, 8, 12, and 16
Time frame: Week 4, 8, 12 and 16
Percentage of Participants in Endoscopic Remission at Week 8
Time frame: Week 8
Percentage of Participants in Clinical Remission at Week 8
Time frame: Week 8
Percentage of Participants With Decrease From Baseline of at Least 1 Point in Rectal Bleeding Mayo Subscore at Weeks 4, 8, 12, and 16
Time frame: Baseline, Weeks 4, 8, 12 and 16
Percentage of Participants With Endoscopic Response at Week 8
Time frame: Week 8
Percentage of Participants in Clinical Response at Week 8
Time frame: Week 8
Change From Baseline in Total Mayo Scores at Week 8
Time frame: Baseline, Week 8
Change From Baseline in Partial Mayo Scores at Weeks 4, 8, 12, and 16
Time frame: Baseline, Weeks 4, 8, 12 and 16
Change From Baseline in Biopsy Histology Scores at Week 8
Time frame: Baseline and Week 8
Change From Baseline in Patient-Reported Rectal Bleeding up to Week 16
Time frame: Baseline and Week 16
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Colitis, Ulcerative
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
58 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing MultiStem low dose and MultiStem high dose in people with Colitis, Ulcerative, run by Pfizer at 58 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 58 sites in United States, Canada, Hungary, Germany, Italy and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Feb 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8 (time frame: Baseline and Week 8). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2016.